Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review – Are They Potential Eradication Regimens?

References

• Ji CR, Liu J, Li YY, et al. Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis. BMJ Open. 2020;10:e037375. doi:10.1136/bmjopen-2020-037375
   Web of Science ®Google Scholar
• O’Connor A, O’Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2017;14(4):230–240. doi:10.1038/nrgastro.2016.195
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, Moss ST. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–238. doi:10.1038/ajg.2016.563
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus Panel. Management of Helicobacter pylori infection-The Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30. doi:10.1136/gutjnl-2016-312288
   PubMed Web of Science ®Google Scholar
• DuPont HL, Pelosini I. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther. 2016;43:3–10.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51(1):36–66. doi:10.1159/000081990
   PubMed Web of Science ®Google Scholar
• Shayto RH, Mrad RA, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol. 2016;22(29):6638–6651. doi:10.3748/wjg.v22.i29.6638
   PubMed Web of Science ®Google Scholar
• Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data. Future Microbiol. 2020;15(12):1185–1196. doi:10.2217/fmb-2020-0084
   Web of Science ®Google Scholar
• Morvan A, Bouguennec N, Graveleau N. ACL injuries before 15 years of age: could the young become an athlete? Arch Orthop Trauma Surg. 2020;140:1055–1063. doi:10.1007/s00402-020-03404-8
   Web of Science ®Google Scholar
• Zhang M. High antibiotic resistance rate: a difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol. 2015;21(48):13432–13437. doi:10.3748/wjg.v21.i48.13432
   PubMed Web of Science ®Google Scholar
• Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol. 2014;20(18):5283–5293. doi:10.3748/wjg.v20.i18.5283
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209–221. doi:10.1111/j.1365-2036.2011.04937.x
   PubMed Web of Science ®Google Scholar
• Higgins J, Thomas J. Cochrane handbook for systematic reviews of interventions [DB/OL]. Available from: https://training.cochrane.org/handbook/current/chapter-07. Accessed October 21, 2021.
   Google Scholar
• Kim HS, Yoon H, Shin DW, et al. Efficacy of and resistance to rifaximin-based quadruple therapy in Helicobacter pylori eradication. Korean J Helicobacter Up Gastrointest Res. 2020;20(3):218–224. doi:10.7704/kjhugr.2020.0021
   Google Scholar
• Konrad P, Chojnacki J, Gąsiorowska A, et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Gastroenterology Rev. 2018;13(3):213–217. doi:10.5114/pg.2018.74228
   Google Scholar
• Ramas M, Donday MG, McNicholla AG, Rudnicki C, Kaczka A, Chojnacki C. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: a Phase IV pilot clinical trial. Gastroenterol Hepato. 2017;40(10):658–662. doi:10.1016/j.gastrohep.2017.05.017
   Web of Science ®Google Scholar
• Sezgin O, Aydın MK, Ateş F, Altıntaş E, Üçbilek E, Yaraş S. Addition of rifaximin and N-Acetyl Cysteine to the standard Helicobacter pylori treatment regimens: is it possible to improve outcomes? J Gastric Disord Ther. 2016;2(2):117.
   Google Scholar
• Yun SP, Seon HG, Chang SO, et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6(4):452–456. doi:10.5009/gnl.2012.6.4.452
   Web of Science ®Google Scholar
• Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci. 2011;26:785–790. doi:10.3346/jkms.2011.26.6.785
   PubMed Web of Science ®Google Scholar
• Nizhevich AA, Shcherbakov PL, Akhmadeeva ÉN, Khasanov RS. Rifaximin in combined treatment of the Helicobacter pylori infection in childhood. Eksp Klin Gastroenterol. 2011;1(1):85–87.
   Google Scholar
• Gasbarrini A, Lauritano EC, Nista EC, et al. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis. 2006;24(1–2):195–200. doi:10.1159/000090330
   Web of Science ®Google Scholar
• Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization Regions. Gastroenterology. 2018;155(5):1372–1382. doi:10.1053/j.gastro.2018.07.007
   PubMed Web of Science ®Google Scholar
• Kalach N, Bontems P, Raymond J. Helicobacter pylori infection in children. Helicobacter. 2017;22(Suppl. 1):e12414. doi:10.1111/hel.12414
   Web of Science ®Google Scholar
• Smith SM, O’Morain C, Mcnamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol. 2019;35(1):6–13. doi:10.1097/MOG.0000000000000497
   PubMed Web of Science ®Google Scholar
• Samantha FT, Soraya MO, Paola BI, et al. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018;12(8):819–827. doi:10.1080/17474124.2018.1496017
   Web of Science ®Google Scholar
• Zhuge L, Wang Y, Wu S, Zhao R, Li Z, Xie Y. Furazolidone treatment for Helicobacter Pylori infection: a systematic review and meta-analysis. Helicobacter. 2018;23(2):e12468. doi:10.1111/hel.12468
   PubMed Web of Science ®Google Scholar
• Goddard AF. Review article: factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther. 1998;12:1175–1184. doi:10.1046/j.1365-2036.1998.00425.x
   PubMed Web of Science ®Google Scholar
• Hou HL, Meng HX, Wen-Jie HU, Wang J-W. The relationship between Helicobacter pylori in oral cavity and the Hp infection in stomach. Zhonghua Kou Qiang Yi Xue Za Zhi. 2003;38(5):327–329.
   Google Scholar
• Krzyżek P, Gościniak G. Oral Helicobacter pylori: interactions with host and microbial flora of the oral cavity. Dent Med Probl. 2018;55(1):75–82. doi:10.17219/dmp/81259
   PubMed Web of Science ®Google Scholar
• Shao CH, Zhang QY, Sun YD, et al. Helicobacter pylori protein response to human bile stress. J Med Microbiol. 2008;57(2):151–158. doi:10.1099/jmm.0.47616-0
   Web of Science ®Google Scholar